View all cases
- Case details
- StatusCase Closed (Patent revoked)ActionCounterclaim for revocationCategoryCounterclaim for revocation
- Parties
- Claimants
- Pfizer Inc.Operating co.
- C.P. Pharmaceuticals International C.V.Operating co.
- Pfizer Europe MA EEIGOperating co.
- Pfizer Manufacturing Deutschland GmbHOperating co.
- Pfizer Italia S.r.L.Operating co.
- Pfizer Ireland Pharmaceuticals Unlimited CompanyOperating co.
- Pfizer Corporation Austria GmbHOperating co.
- Pfizer S.A.Operating co.
- Pfizer Luxembourg SARLOperating co.
- Pfizer ApSOperating co.
- Pfizer OyOperating co.
- Pfizer SASOperating co.
- Pfizer Pharma GmbHOperating co.
- Pfizer S.r.l.Operating co.
- Pfizer B.V.Operating co.
- Laboratórios Pfizer, Lda.Operating co.
- Pfizer Romania S.R.L.Operating co.
- Pfizer ABOperating co.
Representatives- Tobias J. Hessel-Clifford Chance Partnerschaft mbB
Respondents- Enanta Pharmaceuticals, Inc.Operating co.
Representatives- Dirk Schüßler-Langeheine-Hoffmann Eitle
- Division
- Munich LD
- Judges
- —
- Technology
- ChemistryOrganic fine chemistry · Pharmaceuticals
- Language
- English
- First decided
- Oct 29, 2026
- EPO Opposition
- Pfizer Inc.Admissible2026-05-06
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
| Patent revoked | Median days to first decision | |
|---|---|---|
| All UPC | 36% (45/125) | 146 |
| Munich LD | Locked | Locked |
At the UPC: Pfizer Group (32 cases)·Enanta Pharmaceuticals, Inc. (2 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 1 other proceedings
Decisions
- 2026-10-29infringement
Summary: The Munich Local Division revoked EP 4 051 265 (unitary effect) in its entirety for lack of novelty over D1 and D2, the claimed priority being invalid, and dismissed Enanta's infringement action because the patent is not valid. Costs of both the infringement action and the counterclaim are borne by Enanta.
Show the legal issues (5)
- validity of priority claim (same invention, Art. 87 EPC)
- disclosure of individual compounds by generic Markush formula
- novelty Art. 54(2)/(3) EPC over D1 and D2
- partial priority without application to amend
- infringement action dismissed because patent invalid
Documents
- 68cd7797a6c775ee2eb21a19_2026-10-29%20-%20Entscheidung%20in%20UPC_CFI_768-2025%20-%20Enanta%20vs%20Pfizer%20-%20signed%20and%20GDPR-checked.pdf2026-10-29EN